STAT3 and non-small cell lung carcinoma: He et al verified that miR-148a inhibited NSCLC cell proliferation and invasion activity through silencing signal transducer and activator of transcription 3 (STAT3), which highlighted miR-148a/STAT3 axis as a potential target for clinical treatment with NSCLC patients [42].